Description
Ipamorelin is a short‑acting growth‑hormone secretagogue that selectively activates the ghrelin (GHSR‑1a) receptor on pituitary cells to trigger growth hormone (GH) release. Compared with older GHRPs (e.g., GHRP‑6/GHRP‑2), ipamorelin shows minimal impact on cortisol and prolactin at typical doses. In the U.S. it is not FDA‑approved for physique or anti‑aging; products sold online are unregulated for identity and sterility.
Note on vial size: “10 mg” refers to total peptide content per vial in many research/compounding products. Reconstitution volumes and per‑injection amounts should be determined by a clinician.
There are no reviews yet.